Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

p>

Convertible debenture 2,572,873 -

------------ ------------

6,234,082 3,551,040

------------ ------------

------------ ------------

Shareholders' Equity

Capital stock 70,427,920 70,396,170

Warrants 2,550,880 6,180,690

Contributed surplus 11,312,622 7,326,962

Equity component of convertible debenture 1,427,127 -

Deficit (67,591,074) (56,159,163)

------------ ------------

18,127,475 27,744,659

------------ ------------

24,361,557 31,295,699

------------ ------------

------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Loss, Comprehensive Loss and Deficit

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars, except shares)

Three month period ended Six month period ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

------------ ------------ ------------ ------------

$ $ $ $

Revenue

Licensing fees
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email: